Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00518271
Status:
COMPLETED
Last Update Posted:
2007-08-20
First Post:
2007-07-26
Brief Title:
Study Comparing Standard Dose and Reduced Dose Tacrolimus Sirolimus Corticosteroids in Renal Allograft Recipients
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Phase II Open-Label Concentration-Controlled Randomized 6-Month Study of Standard Dose Tacrolimus Sirolimus Corticosteroids Compared to Reduced Dose Tacrolimus Sirolimus Corticosteroids in Renal Allograft Recipients
Status:
COMPLETED
Status Verified Date:
2007-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluated renal graft function based on calculated creatinine clearance at 6 months after transplantation in patients receiving a regimen of reduced or standard dose tacrolimus plus sirolimus and corticosteroids
Detailed Description:
This study evaluated renal graft function based on calculated creatinine clearance at 6 months after transplantation in patients receiving a regimen of reduced or standard dose tacrolimus plus sirolimus and corticosteroids Blood serum creatinine the incidence of biopsy-confirmed acute graft rejection and patient and graft survival were also evaluated at 6 months post transplantation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None